ReviewFrontiers in immunology2025
Understanding the relationship between cuproptosis and the development of hepatocellular carcinoma: implications for targeted therapies.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Dihydrolipoamide dehydrogenase promotes hepatocellular carcinoma progression and modulates cuproptosis-dependent cell death.Functional & integrative genomics · 2026Article
- Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology.Neoplasia (New York, N.Y.) · 2026Review
- Development and validation of a novel T cell exhaustion-related signature to predict prognosis in patients with breast cancer.Discover oncology · 2026Article
- Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.Immunologic research · 2026Article
- Anoctamin 5 as a protective factor in prostate cancer: Insights from WGCNA, machine learning, and experimental analysis, with a focus on the anoctamin family.Translational oncology · 2026Article
- Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients.Translational oncology · 2026Article
- Identification of Mitochondrial Signature Biomarkers and Molecular Mechanisms in Atherosclerotic Tissues and Blood: Combined Single-Cell and Bulk RNA Sequencing Analysis.Molecular neurobiology · 2026Article
- Talin1 is downregulated in testicular germ cell tumors according to combined bioinformatics and experimental approaches.Scientific reports · 2026Article
- From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy.Human mutation · 2026Review
- Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer.Human mutation · 2026Review
- Article
- Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.Frontiers in immunology · 2025Review
- Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy.Frontiers in immunology · 2025Review
- Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.Frontiers in immunology · 2025Review
- Copper metabolism in hepatocellular carcinoma: from molecular mechanisms to therapeutic opportunities.Frontiers in molecular biosciences · 2025Review
- Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.Human mutation · 2025Article
- Genetic Causal Relationship Between Systemic Lupus Erythematosus and Malignant Tumors of the Female Reproductive System: A GWAS Analysis in European Populations.Human mutation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) presents a significant global health challenge, particularly in developing countries where its incidence is markedly elevated. Despite advancements in treatment modalities, the high malignancy, metastatic potential, and drug resistance associated with HCC contribute to poor clinical outcomes, underscoring the necessity for a more profound understanding of its pathogenesis. This review meticulously examines the role of copper apoptosis, a novel form of programmed cell death linked to dysregulated copper metabolism, in the development and progression of HCC. By conducting a comprehensive review of recent literature and experimental studies, we elucidate the molecular mechanisms through which excess copper induces oxidative stress, pyroptosis, and ferroptosis, thereby influencing tumorigenesis and progression. This review offers valuable insights into the intricate relationship between copper metabolism and HCC, positioning copper apoptosis as a potential therapeutic target to enhance treatment strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.